Clinical Trial Update: A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of CF102 (piclidenoson) in chronic hepatitis C genotype 1 has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• CF102 (piclidenoson)

Snippet

Sponsor: Can-Fite BioPharma | Conditions: Chronic Hepatitis C | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-04-15